| Subgroup identification from randomized clinical trial data JC Foster, JMG Taylor, SJ Ruberg Statistics in medicine 30 (24), 2867-2880, 2011 | 695 | 2011 |
| Effect of longer-interval vs standard dosing of zoledronic acid on skeletal events in patients with bone metastases: a randomized clinical trial AL Himelstein, JC Foster, JL Khatcheressian, JD Roberts, DK Seisler, ... Jama 317 (1), 48-58, 2017 | 314 | 2017 |
| Accrual of older patients with breast cancer to alliance systemic therapy trials over time: protocol A151527 RA Freedman, JC Foster, DK Seisler, JM Lafky, HB Muss, HJ Cohen, ... Journal of Clinical Oncology 35 (4), 421, 2017 | 84 | 2017 |
| Cost-effectiveness analysis of monthly zoledronic acid, zoledronic acid every 3 months, and monthly denosumab in women with breast cancer and skeletal metastases: CALGB 70604 … CL Shapiro, JP Moriarty, S Dusetzina, AL Himelstein, JC Foster, ... Journal of Clinical Oncology 35 (35), 3949, 2017 | 69 | 2017 |
| Long-term effects of pre-placement risk factors on children’s psychological symptoms and parenting stress among families adopting children from foster care E Nadeem, J Waterman, J Foster, E Paczkowski, TR Belin, J Miranda Journal of Emotional and Behavioral Disorders 25 (2), 67-81, 2017 | 65 | 2017 |
| Updated standardized definitions for efficacy end points (STEEP) in adjuvant breast cancer clinical trials: STEEP version 2.0 SM Tolaney, E Garrett-Mayer, J White, VS Blinder, JC Foster, ... Journal of Clinical Oncology 39 (24), 2720, 2021 | 62 | 2021 |
| Outcomes evaluation of a weekly nurse practitioner-managed symptom management clinic for patients with head and neck cancer treated with chemoradiotherapy H Mason, MB DeRubeis, JC Foster, JMG Taylor, FP Worden Oncology nursing forum 40 (6), 581, 2013 | 59 | 2013 |
| Phase II study of atezolizumab in advanced alveolar soft part sarcoma (ASPS) AR Naqash, GH O’Sullivan Coyne, N Moore, E Sharon, N Takebe, ... J Clin Oncol 39 (15_suppl), 11519, 2021 | 46 | 2021 |
| Reader reaction to “a robust method for estimating optimal treatment regimes” by Zhang et al.(2012) JMG Taylor, W Cheng, JC Foster Biometrics 71 (1), 267-273, 2015 | 36 | 2015 |
| Variable selection in monotone single‐index models via the adaptive LASSO JC Foster, JMG Taylor, B Nan Statistics in medicine 32 (22), 3944-3954, 2013 | 35 | 2013 |
| Molecular profiling-based assignment of cancer therapy (NCI-MPACT): A randomized multicenter phase II trial AP Chen, S Kummar, N Moore, LV Rubinstein, Y Zhao, PM Williams, ... JCO Precision Oncology 5, 133-144, 2021 | 27 | 2021 |
| Simple subgroup approximations to optimal treatment regimes from randomized clinical trial data JC Foster, JMG Taylor, N Kaciroti, B Nan Biostatistics 16 (2), 368-382, 2015 | 24 | 2015 |
| Atezolizumab for advanced alveolar soft part sarcoma AP Chen, E Sharon, G O’Sullivan-Coyne, N Moore, JC Foster, JS Hu, ... New England Journal of Medicine 389 (10), 911-921, 2023 | 20 | 2023 |
| Risk of acute myeloid leukemia and myelodysplastic syndrome among older women receiving anthracycline-based adjuvant chemotherapy for breast cancer on Modern Cooperative Group … RA Freedman, DK Seisler, JC Foster, JA Sloan, JM Lafky, GG Kimmick, ... Breast cancer research and treatment 161, 363-373, 2017 | 19 | 2017 |
| Assessment of cancer therapy evaluation Program advocacy and inclusion rates of people living with HIV in anti–PD1/PDL1 clinical trials JE Reuss, D Stern, JC Foster, R Ramaswami, K Lurain, HX Chen, ... JAMA Network Open 3 (12), e2027110-e2027110, 2020 | 18 | 2020 |
| Permutation testing for treatment–covariate interactions and subgroup identification JC Foster, B Nan, L Shen, N Kaciroti, JMG Taylor Statistics in biosciences 8, 77-98, 2016 | 18 | 2016 |
| Pre-placement risk and longitudinal cognitive development for children adopted from foster care JM Waterman, E Nadeem, E Paczkowski, JC Foster, JA Lavner, T Belin, ... Child welfare 92 (4), 9, 2013 | 17 | 2013 |
| Clinical activity of single-agent cabozantinib (XL184), a multi-receptor tyrosine kinase inhibitor, in patients with refractory soft-tissue sarcomas G O'Sullivan Coyne, S Kummar, J Hu, K Ganjoo, WA Chow, KT Do, J Zlott, ... Clinical Cancer Research 28 (2), 279-288, 2022 | 11 | 2022 |
| Standardized definitions for efficacy end points in neoadjuvant breast cancer clinical trials: NeoSTEEP JK Litton, MM Regan, L Pusztai, HS Rugo, SM Tolaney, E Garrett-Mayer, ... Journal of Clinical Oncology 41 (27), 4433, 2023 | 10 | 2023 |
| Trial design considerations to increase older adult accrual to National Cancer Institute clinical trials J Le-Rademacher, S Mohile, J Unger, MF Hudson, J Foster, S Lichtman, ... JNCI Monographs 2022 (60), 135-141, 2022 | 10 | 2022 |
